Catalyst Pharmaceuticals insider sales: 30,000-share Form 144; recent disposals total 80,000

Rhea-AI Filing Summary

Catalyst Pharmaceuticals (CPRX) filing a Form 144 notifies of a proposed sale of 30,000 common shares to be executed through Fidelity Brokerage Services on 09/08/2025 with an aggregate market value of $609,035.49 based on the filing. The shares were acquired through options granted 12/19/2018 and the reported payment method for the sale is cash. The filing also reports recent open-market disposals by the same person: 20,000 shares sold on 09/03/2025 for $401,514.00 and 30,000 shares sold on 09/04/2025 for $585,642.00. The filer attests no undisclosed material adverse information.

Positive

• Clear compliance: Form 144 filed as LIVE and discloses broker, amounts, dates, and source of shares (options).
• Specific transaction detail: Provides exact share counts and gross proceeds for recent sales, aiding transparency.

Negative

• Insider selling: Recent disposals total 80,000 shares across 09/03–09/08/2025 which may be viewed negatively by some investors.
• Concentration timing: Multiple sales within days could raise questions about insider liquidity needs or sentiment.

Insights

Securities Compliance Analyst

TL;DR: Routine Rule 144 notice showing option-derived shares being sold and recent near-term insider sales; appears procedural and compliant.

The Form 144 discloses a planned sale of 30,000 common shares via a broker and documents that the shares derive from options granted in 2018. The filing includes two recent sales by the same individual within the past week, with specified share amounts and gross proceeds, which is relevant for monitoring insider selling patterns. The notice contains the standard attestation about lack of undisclosed material information, aligning with Rule 144 procedural requirements.

Financial Analyst

TL;DR: Insider liquidity events totaling 80,000 shares reported across early September; impact appears limited absent further context on holdings or company size.

The document lists a proposed 09/08/2025 sale of 30,000 shares valued at about $609k and recent sales of 20,000 and 30,000 shares on 09/03 and 09/04 generating roughly $401.5k and $585.6k respectively. Without information on the seller's remaining ownership or total float impact, this represents disclosed insider selling activity but is not, by itself, a company financial development. Investors would need ownership context to assess valuation impact.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	30000	609035.49	122391010	09/08/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/08/2025	Options Granted 12/19/2018	Issuer			30000	09/08/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Brian D. Elsbernd 355 Alhambra Circle Suite 801 Coral Gables FL 33134	Common	09/03/2025	20000	401514.00
Brian D. Elsbernd 355 Alhambra Circle Suite 801 Coral Gables FL 33134	Common	09/04/2025	30000	585642.00

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Catalyst Pharmaceuticals' (CPRX) Form 144 report?

The Form 144 reports a proposed sale of 30,000 common shares09/08/2025 valued at $609,035.49, and recent sales of 20,000 and 30,000 shares on 09/03/2025 and 09/04/2025.

Who is listed as the seller in the Form 144 for CPRX?

The recent sales reported list Brian D. Elsbernd at the provided address as the seller for the 09/03 and 09/04 transactions.

What is the source of the shares being sold under the Form 144?

The 30,000 shares to be sold were acquired via options granted 12/19/2018 with the acquisition/sale date recorded as 09/08/2025 and payment method as cash.

How much did the recent insider sales generate?

The filing reports gross proceeds of $401,514.00 for 20,000 shares sold on 09/03/2025 and $585,642.00 for 30,000 shares sold on 09/04/2025.

Does the filing indicate any undisclosed material information?

The signer attests they do not know of any material adverse information about the issuer that has not been publicly disclosed.

Through which broker will the proposed sale be executed?

The proposed 30,000-share sale is to be executed through Fidelity Brokerage Services LLC in Smithfield, RI.